Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Minority Interest (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Minority Interest for 4 consecutive years, with $35.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Minority Interest rose 0.57% to $35.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $35.5 million, a 0.57% increase, with the full-year FY2024 number at $35.1 million, up 17.82% from a year prior.
  • Minority Interest was $35.5 million for Q3 2025 at Gyre Therapeutics, down from $37.4 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $37.4 million in Q2 2025 to a low of $29.7 million in Q4 2022.
  • A 4-year average of $33.8 million and a median of $35.1 million in 2024 define the central range for Minority Interest.
  • Peak YoY movement for Minority Interest: rose 0.28% in 2023, then rose 17.82% in 2024.
  • Gyre Therapeutics' Minority Interest stood at $29.7 million in 2022, then increased by 0.28% to $29.8 million in 2023, then rose by 17.82% to $35.1 million in 2024, then grew by 1.17% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Minority Interest are $35.5 million (Q3 2025), $37.4 million (Q2 2025), and $36.2 million (Q1 2025).